Ani Pharmaceuticals (ANIP) Invested Capital (2010 - 2026)

Ani Pharmaceuticals has disclosed Invested Capital across 17 years of filings, most recently posting $871.0 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $871.0 million, up 2.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $871.0 million (up 2.24% YoY), and the FY2025 annual result was $853.5 million, up 159.98% from the prior year.
• Invested Capital came in at $871.0 million for Q1 2026 at Ani Pharmaceuticals, up from $853.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $871.0 million in Q1 2026 to a low of $205.1 million in Q3 2022.
• The 5-year median for Invested Capital is $328.3 million (2024), against an average of $526.1 million.
• Peak annual rise in Invested Capital reached 268.96% in 2025, while the deepest fall reached 70.66% in 2025.
• Ani Pharmaceuticals' Invested Capital stood at $700.9 million in 2022, then slumped by 58.05% to $294.0 million in 2023, then rose by 11.67% to $328.3 million in 2024, then soared by 159.98% to $853.5 million in 2025, then advanced by 2.05% to $871.0 million in 2026.
• The last three Invested Capital figures came in at $871.0 million (Q1 2026), $853.5 million (Q4 2025), and $822.7 million (Q3 2025), per Business Quant data.